Book a demo

Chemical intelligence powered by cypris.ai

Lupex

(2S)-2-[[(2R)-2-[[2-[[2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid · also: MET-enkephalin, Methionine enkephalin

FormulaC27H35N5O7S
Mol. weight573.665
PubChem CID6427062
InChIKeyYFGBQHOOROIVKG-BHIFYINESA-N
SMILESCSCC[C@@H](C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](CC2=CC=C(C=C2)O)N
2,554Patents
402Research papers
93Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Purdue Pharma LP174
2Allergan Inc118
3Aventis Pharmaceuticals Inc56
4Bausch Health Ireland Ltd56
5Vertex Pharmaceuticals Inc50
6Janssen R&D Ireland ULC47
7Pharmacia LLC47
8Durect Corp46
9Japan Tobacco Inc45
10Leland Stanford Junior University43

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations1,744
2A61PTherapeutic activity (drug indications)1,731
3C07KPeptides950
4C07DHeterocyclic compounds611
5C12NMicroorganisms, enzymes393
6G01NInvestigating / analysing materials390
7C07CAcyclic and carbocyclic compounds139
8C12QMeasuring/testing involving enzymes118
9C12YEnzyme nomenclature (EC numbers)118
10Y02AClimate change adaptation98

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Syncretic protein product of human methionine enkephalin interferon alpha-m with anti-HSV infection and easy pain2003BEIJING DONGKANGLONG VIRUS BIOTECHNOLOGY ENGINEERING RESEARCH CENTRE10
USE OF MELANIN CONCENTRATING HORMONE AND MET-ENKEPHALIN AS THERAPEUTIC AGENTS2009Mondobiotech Laboratories AG4
Use of compound methionine enkephalin as medicine for treating brain cancer, kidney cancer and liver cancer2005LUO ZHINONG4
USE OF MET-ENKEPHALIN AS A THERAPEUTIC AGENT2009Mondobiotech Laboratories AG3
Application of compounds methionine enkephalin for preparing medicine for curing blood medulla hematopoietic system cancer2008DAN FENGPING2

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Neuropeptides and Animal Physiology3
2Pain Mechanisms and Treatments2
3Anesthesia and Sedative Agents1
4Circadian rhythm and melatonin1
5Drug Transport and Resistance Mechanisms1
6Hormonal Regulation and Hypertension1
7Lipid Membrane Structure and Behavior1
8Neurological disorders and treatments1
9Parasite Biology and Host Interactions1
10Prostate Cancer Treatment and Research1

Technology trend analysis

Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.

See Cypris in action

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Bahram Sayyaf DezfuliUniversity of Ferrara9
2Christoph SteinCharité - Universitätsmedizin Berlin7
3Luisa GiariUniversity of Ferrara6
4Alexander BrackUniversity of Würzburg4
5Bernd A. BergFlorida State University4
6Christopher W. VaughanRoyal North Shore Hospital4
7David C. YeomansStanford University4
8Dominika ŁabuzFranklin University4
9Edi SimoniUniversity of Ferrara4
10George B. StefanoSUNY Old Westbury4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Lupex?

Lupex has the molecular formula C27H35N5O7S with a molecular weight of 573.665. Its canonical IUPAC name is (2S)-2-[[(2R)-2-[[2-[[2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid, and it is also known by the synonyms MET-enkephalin and Methionine enkephalin.

How much patent activity surrounds Lupex?

Lupex has substantial patent coverage with 2554 total patents identified. In the last three years, there have been 93 patents filed related to this compound. The most active patent year was 2018 with 105 patents, followed by 2016 with 101 patents.

Which organizations hold the most patents on Lupex?

The leading patent assignees for Lupex are Purdue Pharma LP with 174 patents, followed by Allergan Inc with 118 patents, Aventis Pharmaceuticals Inc with 56 patents, and Bausch Health Ireland Ltd also with 56 patents. Other significant patent holders include Vertex Pharmaceuticals Inc, Janssen R&D Ireland ULC, Pharmacia LLC, Durect Corp, Japan Tobacco Inc, and Leland Stanford Junior University.

What research topics are associated with Lupex studies?

Research on Lupex spans multiple areas including Neuropeptides and Animal Physiology, Pain Mechanisms and Treatments, Neurological disorders and treatments, and Neurotransmitter Receptor Influence on Behavior. Key published works examine topics such as protein structure and dynamics of Met-enkephalin, stress responses, and opioid receptor function in the nucleus accumbens.

What are the primary patent classification areas for Lupex?

Lupex patents are concentrated in pharmaceutical and chemical classification areas. The largest category is A61K (Preparation of medicinal compounds) with 1744 patents, followed closely by A61P (Specific therapeutic activity of chemical compounds) with 1730 patents. Significant coverage also exists in C07K (Organic macromolecular compounds) with 950 patents and C07D (Heterocyclic compounds) with 611 patents.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial